tag:blogger.com,1999:blog-19490962.post3447959099356801562..comments2023-12-10T10:06:41.979+00:00Comments on mutations of mortality: array CGHTerry Hamblinhttp://www.blogger.com/profile/06346629921055055879noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-19490962.post-55841784300690772522011-02-08T18:11:02.237+00:002011-02-08T18:11:02.237+00:00High resolution ACGH is just one more step in the ...High resolution ACGH is just one more step in the unravelling of the genetic lesions in CLL. It is currently much more expensive than FISH and for looking for the 5 commonest abnormalities - del 11q, del 13q. del 17p, del 6q and trisomy 12, FISH is preferred. CGH is a research tool for seeking moderate sized changes from genomic DNA. It could be used to determine the size of deletions, which may be important for del 13q. SNP analysis will be required for single nucleotide changes. Unsuspected balanced translocations might require spectral karyotyping. These techniques are complementary. Even conventional G-banding is usually sufficient for <30% mosaicism. Epigenetics will be needed to complete the picture. At the moment it is horses for courses.Terry Hamblinhttps://www.blogger.com/profile/06346629921055055879noreply@blogger.comtag:blogger.com,1999:blog-19490962.post-15954184782290448782011-02-08T17:28:46.241+00:002011-02-08T17:28:46.241+00:00Terry,
Given the advantages of both whole genome ...Terry,<br /><br />Given the advantages of both whole genome CGH array and HD Oligo scan used to characterize the MDR will these scans play an important role toward the desired goal of sub-typing the CLL population with the hope for better targeted therapy usage?<br /><br />Among the shortcomings for CGH are listed the inability to detect point mutations, intragenic deletions, duplications, balanced chromosomal aberrations including Robertsonian translocations, reciprocal translocations, inversions and balanced insertions not to omit mosaicism <30%. That sounds like a lot of categories but how important are they to judge the overall value of the scans?<br /><br />In the category of balanced translocations, is the coding for correct protein production affected to an important degree in disease progression? Does this also need to be addressed for quality sub-typing?<br /><br />How much of a weakness for CGH is the need for the reference genome to be normal?<br /><br />If the clinical utility of CGH at this time is premature in your view, what class of targeted drug therapies will need this class of scanning?<br /><br />I had better quit but find this topic most interesting.<br /><br />Hope this finds you coping well.<br /><br />WWWWaynehttps://www.blogger.com/profile/12333087913528941756noreply@blogger.com